Healthcare
Stella Diagnostics Inc.(SLDX)
Live Price
Offline$0.0103
+0.00% today
1Y Change
-71.43%
Window
Jun 20, 2025 โ May 29, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- -277.4%
- Dividend Yield
- 0.0%
Coverage: 237 bars ยท Jun 20, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stella Diagnostics Inc. (SLDX) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 71.4% across the available one-year price window (Jun 20, 2025 โ May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -277.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -277.4%, free cash flow -2151.5% with operating margin -196.7% and ROIC 24.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SLDX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-196.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on Sep 30, 2023, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -277.4%, with operating margin around -196.7%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLDX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SLDX Max Drawdown
-78.63%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SLDX and SPY.
Company Overview
Stella Diagnostics Inc.
Other OTC
Stella Diagnostics, Inc., a molecular diagnostics-based company, focuses on enhancing patient management strategies for people living with severe esophageal diseases. Its clinical assays offer physicians insight into the molecular properties of patients' tissue to determine if the disease is stable, progressing, or turning cancerous. The company is also developing diagnostic tools that provides molecular information for providers as compared to the screening protocols. The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in April 2021. Stella Diagnostics, Inc. is based in Salt Lake City, Utah.
- Leadership
- David Seaburg
- IPO Date
- Apr 16, 2021
- Employees
- 2
- Street Address
- 50 West Broadway
- Mailing
- Salt Lake City, UT, 84104
- Region
- Salt Lake City, UT, US
- Reporting Currency
- USD
- Investor Line
- 561 265 3272
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.8
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -277.4%
- Free Cash Flow
- -2151.5%
Profitability
- Gross Margin
- -40.4%
- Operating Margin
- -196.7%
- Net Margin
- -227.5%
- ROE
- 17.1%
- ROIC
- 24.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.